Forum Energy's 15min chart shows Bollinger Bands expanding upward, bullish marubozu formation.

Based on the 15-minute chart for Forum Energy, the Bollinger Bands are expanding upward and the recent Bullish Marubozu at 08/25/2025 11:45 indicates that market trends are being driven by strong buying interest. As a result, it is likely that the bullish momentum will continue, as buyers maintain control of the market.

Forum Energy Technologies' (FET) 15-minute chart has exhibited a significant shift in market trends, signaling potential bullish momentum. On August 25, 2025, at 11:45, the chart displayed a Bullish Marubozu candle, indicating strong buying interest. This was accompanied by an upward expansion of Bollinger Bands, suggesting increasing volatility and a potential breakout in the stock price.

The Bullish Marubozu pattern is a bullish signal, as it signifies a strong buying pressure. The absence of wicks on the candle indicates that the price moved in a single direction, with buyers controlling the market. This pattern is often followed by a continuation of the upward trend, as buyers maintain control [1].

The Bollinger Bands' upward expansion also suggests increasing volatility. Bollinger Bands consist of a simple moving average and two standard deviations above and below it. When the bands expand, it indicates higher volatility, which can lead to significant price movements. The upward expansion of the bands further supports the bullish momentum, as it suggests that the price is poised for a breakout in the upward direction [1].

These technical indicators are part of a broader trend observed in several other stocks. While these signals provide insights into potential stock price movements, it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions.

Positive Outlook:
- Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1].
- Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1].
- CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1].
- Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1].
- Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1].
- Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1].
- Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1].
- Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1].
- JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1].
- Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1].
- Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1].
- MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1].
- Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1].
- Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1].
- Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1].
- Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1].
- Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1].
- Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1].
- Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1].
- Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1].
- PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1].
- Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].

References:
[1] https://www.ainvest.com/news/pulse-biosciences-15min-chart-shows-bollinger-bands-narrowing-kdj-death-cross-detected-2508/
[2] https://www.ainvest.com/news/urgent-ly-2025-q2-earnings-5